It is a bit of a perfect example of the successful collaboration between a company carrying disruptive technology and the firepower of a major industrialist.
With an innovation in mRNA, the young German SME BioNTech and its partner Pfizer are at the forefront in the production of vaccines against the coronavirus.
In France, the crisis has made the need to build bridges between the French deeptech companies, capable of breakthrough innovation, and the major industrial players even more acute.
Read also:
Biotech: the long-awaited rise of French start-ups
Only the latter can help turn technological advances into large-scale solutions.
On this necessary “mixing” between the industry of the future and disruptive technologies depend both the competitiveness of French players and the country's reindustrialisation, two main priorities of the recovery plan.
Supported by the government, the public investment bank, Bpifrance and France Industrie, an organization representing French industry,
This article is for subscribers only.
You have 74% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in